TP53 and B-cell chronic lymphocytic leukemia: Prolonged PFS was also observed in subgroup analysis of TP53 disrupted CLL in the ILLUMINATE trial favoring ibrutinib with obintuzumab to chlorambucil with obintuzumab in previously untreated patients [58].